Antibody maker Epitomics this week announced that it has signed a contract with SAIC-Frederick to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer program.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma. The antibodies will be used for immuno-enrichment of target peptides in mass spec workflows like stable isotope standards and capture by anti-peptide antibodies, or SISCAPA, and immuno-MALDI mass spec.